| Personalis is a cancer genomics company transforming the development of therapies by providing molecular data about each patient's cancer and immune response. Co. designed its NeXT Platform to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to various cancer panels that cover roughly only 50 to 500 genes. Co. has launched NeXT Liquid Biopsy, which is a liquid biopsy assay that analyzes all of the approximately 20,000 human genes versus the narrowly focused liquid biopsy assays that are available. The PSNL average annual return since 2019 is shown above.
The Average Annual Return on the PSNL average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PSNL average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PSNL average annual return calculation with any dividends reinvested as applicable (on ex-dates).